BioSpace News Archive

Karuna Therapeutics, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2021, and provided a general business update.

Aerie Pharmaceuticals, Inc. today announced that Gary Sternberg, M.D., M.B.A., will join the Company as Chief Medical Officer (CMO), effective March 1, 2022.

AdaptHealth Corp. announced today financial results for the fourth quarter and fiscal year ended December 31, 2021.

Immuneering Corporation today announced that management will participate in two March investor conferences to share commentary around the Company’s pipeline, platform, and business strategy.

Eagle Pharmaceuticals, Inc. today announced that the Company will release its 2021 fourth quarter and full year financial results on Monday, March 7, 2022, before the market opens.

ANI Pharmaceuticals appoints Mary Pao, M.D., Ph.D., as Chief Medical Officer, Rare Disease, and Elizabeth Powell, J.D., as Chief Compliance Officer and Head of Legal, Rare Disease.

ProQR Therapeutics N.V. reported its financial and operating results for the fourth quarter and full year ended December 31, 2021, and provided a business update.

EyePoint Pharmaceutical, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 3, 2022 to report its fourth quarter and full-year 2021 financial results and highlight recent corporate developments.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2021 financial results on Thursday, March 10, 2022 before the open of the U.S. financial markets.

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, reported business highlights and financial results for the fourth quarter and year ended Dec. 31, 2021.